{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:11Z","timestamp":1793321771029,"version":"4.5.0"},"reference-count":201,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.beem.2021.101515","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T01:46:26Z","timestamp":1615427186000},"page":"101515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Stefano","family":"Frara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Allora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Loli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tradati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Massimo","family":"Ulivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2021.101515_bib1","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/TCRM.S12952","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"6","author":"Mancini","year":"2010","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.beem.2021.101515_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib4","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1210\/jcem.86.12.8066","article-title":"Glucocorticoid-induced osteoporosis: summary of a workshop","volume":"86","author":"Canalis","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"17","author":"Mazziotti","year":"2006","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2021.101515_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11102-005-1051-2","article-title":"Cushing\u2019s syndrome and bone","volume":"7","author":"Mancini","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2021.101515_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000443866","article-title":"Skeletal fragility in endogenous hypercortisolism","volume":"46","author":"Mazziotti","year":"2016","journal-title":"Front Horm Res"},{"key":"10.1016\/j.beem.2021.101515_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1043-2760(00)00234-4","article-title":"Glucocorticoid-induced osteoporosis","volume":"11","author":"Manelli","year":"2000","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib10","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-10-0125","article-title":"Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency","volume":"163","author":"Mazziotti","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","article-title":"Bone safety of dual-release hydrocortisone in patients with hypopituitarism","volume":"60","author":"Frara","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2021.101515_bib14","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib15","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.beem.2021.101515_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","article-title":"Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions Part 2: trabecular bone score","volume":"18","author":"Silva","year":"2015","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.beem.2021.101515_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jocd.2015.06.006","article-title":"Measurement of hip geometry-technical background","volume":"18","author":"Beck","year":"2015","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.beem.2021.101515_bib18","doi-asserted-by":"crossref","first-page":"590139","DOI":"10.3389\/fmed.2020.590139","article-title":"Beyond bone mineral density: a new dual X-ray absorptiometry index of bone strength to predict fragility fractures, the bone strain index","volume":"7","author":"Ulivieri","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.beem.2021.101515_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-014-0280-4","article-title":"Utility of the trabecular bone score (TBS) in secondary osteoporosis","volume":"47","author":"Ulivieri","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s198-002-8337-y","article-title":"Improving risk assessment: hip geometry, bone mineral distribution and bone strength in hip fracture cases and controls. The EPOS study. European Prospective Osteoporosis Study","volume":"13","author":"Crabtree","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jocd.2015.06.005","article-title":"Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions Part 1: hip geometry","volume":"18","author":"Broy","year":"2015","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.beem.2021.101515_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190477","article-title":"The role of carboxy-terminal cross-linking telopeptide of type I collagen, dual x-ray absorptiometry bone strain and Romberg test in a new osteoporotic fracture risk evaluation: a proposal from an observational study","volume":"13","author":"Ulivieri","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2021.101515_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13018-019-1100-6","article-title":"Reference markers of bone turnover for prediction of fracture: a meta-analysis","volume":"14","author":"Tian","year":"2019","journal-title":"J\u00a0Orthop Surg Res"},{"key":"10.1016\/j.beem.2021.101515_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","article-title":"Association between vertebral fracture and increased mortality in osteoporotic patients","volume":"18","author":"Jalava","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2147\/CIA.S190440","article-title":"Health-related quality of life in Romanian postmenopausal women with osteoporosis and fragility fractures","volume":"13","author":"Ciubean","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.beem.2021.101515_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12891-015-0733-9","article-title":"Prevalence of fractures in women with rheumatoid arthritis and\/or systemic lupus erythematosus on chronic glucocorticoid therapy","volume":"16","author":"Rentero","year":"2015","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.beem.2021.101515_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-006-0306-8","article-title":"Enhanced prediction of fracture risk combining vertebral fracture status and BMD","volume":"18","author":"Siris","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tem.2020.12.004","article-title":"Effects of medical treatment of prostate cancer on bone health","volume":"32","author":"Formenti","year":"2021","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","article-title":"New advances in imaging osteoporosis and its complications","volume":"42","author":"Griffith","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","article-title":"Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women","volume":"20","author":"Bonadonna","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","article-title":"Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11080","article-title":"Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"2","author":"Pedersini","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.beem.2021.101515_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","article-title":"Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study","volume":"97","author":"Pedersini","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101515_bib36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12020-016-1078-3","article-title":"High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures","volume":"54","author":"Maffezzoni","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/js.2018-00091","article-title":"High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma","volume":"2","author":"Frara","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.beem.2021.101515_bib38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib40","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1210\/clinem\/dgaa738","article-title":"Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes","volume":"106","author":"di Filippo","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib41","series-title":"Intracranial tumours: notes upon a series of two thousand verified cases with surgical-mortality percentges pertaining thereto","author":"Cushing","year":"1932"},{"key":"10.1016\/j.beem.2021.101515_bib42","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2021.101515_bib43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1210\/jc.2002-021518","article-title":"Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of E. Gender-related differences in the presentation and course of Cushing\u2019s disease","volume":"88","author":"Pecori Giraldi","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib44","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2020.3.FOCUS2044","article-title":"Development and validation of the disease-specific QOL-CD quality of life questionnaire for patients with Cushing\u2019s disease","volume":"48","author":"Cusimano","year":"2020","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.beem.2021.101515_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-015-0640-y","article-title":"Quality of life in Cushing\u2019s syndrome","volume":"18","author":"Santos","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2021.101515_bib46","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1530\/EJE-16-0289","article-title":"Mechanisms IN endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review","volume":"175","author":"Chiodini","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib47","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223432","article-title":"Beyond the metabolic syndrome: visceral and marrow adipose tissues impair bone quantity and quality in Cushing\u2019s disease","volume":"14","author":"Batista","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2021.101515_bib49","first-page":"33","article-title":"Autonomous hypercortisolism: definition and clinical implications","volume":"44","author":"Reimondo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib50","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00268-007-9394-7","article-title":"Bone mineral density before and after surgical cure of Cushing\u2019s syndrome due to adrenocortical adenoma: prospective study","volume":"32","author":"Kawamata","year":"2008","journal-title":"World J Surg"},{"key":"10.1016\/j.beem.2021.101515_bib51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","article-title":"Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing\u2019s disease: a prospective study","volume":"58","author":"Di Somma","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.50.1","article-title":"Osteoporosis is more prevalent in adrenal than in pituitary Cushing\u2019s syndrome","volume":"50","author":"Ohmori","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2021.101515_bib53","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1210\/jc.2005-0582","article-title":"Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status","volume":"91","author":"Tauchmanova","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","article-title":"Bone complications in patients with Cushing\u2019s syndrome: looking for clinical, biochemical, and genetic determinants","volume":"25","author":"Trementino","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib56","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cen.12812","article-title":"Bone density and microarchitecture in endogenous hypercortisolism","volume":"83","author":"dos Santos","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib57","first-page":"1863","article-title":"Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome","volume":"83","author":"Chiodini","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02067","article-title":"Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing\u2019s syndrome: a prospective, long-term study","volume":"154","author":"Kristo","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib59","first-page":"492","article-title":"Effect of hypercortisolism on bone mineral density and bone metabolism: a potential protective effect of adrenocorticotropic hormone in patients with Cushing\u2019s disease","volume":"46","author":"Guo","year":"2018","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.beem.2021.101515_bib60","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cen.13743","article-title":"Assessment of vertebral microarchitecture in overt and mild Cushing\u2019s syndrome using trabecular bone score","volume":"89","author":"Vinolas","year":"2018","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib62","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib63","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.beem.2021.101515_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","article-title":"Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis","volume":"16","author":"Dalle Carbonare","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101515_bib67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3899\/jrheum.140752","article-title":"Trabecular bone score in female patients with systemic sclerosis: comparison with rheumatoid arthritis and influence of glucocorticoid exposure","volume":"42","author":"Koumakis","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2021.101515_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11657-015-0244-1","article-title":"The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome","volume":"10","author":"Belaya","year":"2015","journal-title":"Arch Osteoporos"},{"issue":"4","key":"10.1016\/j.beem.2021.101515_bib69","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-20-1396","article-title":"Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study","volume":"184","author":"Li","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib70","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-07-0137","article-title":"Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism","volume":"157","author":"Tauchmanova","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib71","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-007-0514-x","article-title":"Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing\u2019s syndrome","volume":"19","author":"Futo","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101515_bib73","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib75","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib76","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00198-004-1616-3","article-title":"Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing\u2019s syndrome","volume":"15","author":"Minetto","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","article-title":"Spontaneous recovery of bone mass after cure of endogenous hypercortisolism","volume":"15","author":"Randazzo","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2021.101515_bib78","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-020-01496-y","article-title":"Assessment of non-traumatic vertebral fractures in Cushing\u2019s syndrome patients","author":"Apaydin","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2021.101515_bib79","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/bonekey.2016.42","article-title":"Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing\u2019s syndrome","volume":"5","author":"Belaya","year":"2016","journal-title":"BoneKEy Rep"},{"key":"10.1016\/j.beem.2021.101515_bib80","first-page":"2859","article-title":"Bone mineral density and bone turnover before and after surgical cure of Cushing\u2019s syndrome","volume":"80","author":"Hermus","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib81","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2265.2004.01968.x","article-title":"Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing\u2019s syndrome","volume":"60","author":"Karavitaki","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib82","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00198-009-0978-y","article-title":"Bone turnover in patients with endogenous Cushing\u2019s syndrome before and after successful treatment","volume":"21","author":"Szappanos","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s001980170143","article-title":"Quantitative ultrasound of bone and markers of bone turnover in Cushing\u2019s syndrome","volume":"12","author":"Cortet","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2002.01602.x","article-title":"Bone metabolism and mass in women with Cushing\u2019s syndrome and adrenal incidentaloma","volume":"57","author":"Francucci","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib85","first-page":"3303","article-title":"Serum markers of bone and collagen turnover in patients with Cushing\u2019s syndrome and in subjects with adrenal incidentalomas","volume":"82","author":"Osella","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-2007-1010755","article-title":"Osteocalcin levels in Cushing\u2019s disease before and after treatment","volume":"20","author":"Sartorio","year":"1988","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2021.101515_bib87","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1530\/eje.0.1410126","article-title":"Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing\u2019s syndrome","volume":"141","author":"Godang","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib88","first-page":"464","article-title":"Spontaneous remission of corticosteroid osteopenia after successful surgical treatment of Cushing\u2019s syndrome. A cross-sectional study","volume":"136","author":"Stepan","year":"1997","journal-title":"Cas Lek Cesk"},{"key":"10.1016\/j.beem.2021.101515_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-14-0747","article-title":"Body composition and bone mineral density in women with Cushing\u2019s syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity","volume":"172","author":"Ragnarsson","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2265.1992.tb01437.x","article-title":"Normal bone mineral density following cure of Cushing\u2019s syndrome","volume":"36","author":"Manning","year":"1992","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib91","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s001980170025","article-title":"Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing\u2019s syndrome","volume":"12","author":"Luisetto","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib92","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1359\/jbmr.090505","article-title":"Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing\u2019s syndrome","volume":"24","author":"Barahona","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib93","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2265.1998.00486.x","article-title":"Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing\u2019s disease","volume":"48","author":"Di Somma","year":"1998","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib94","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1210\/jcem.86.2.7178","article-title":"The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis","volume":"86","author":"Osella","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib95","first-page":"1440","article-title":"Subclinical Cushing\u2019s syndrome in patients with adrenal incidentaloma: clinical and biochemical features","volume":"85","author":"Rossi","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib96","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/jcem.84.7.5856","article-title":"Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism","volume":"84","author":"Torlontano","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib97","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1210\/jc.2003-031413","article-title":"Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status","volume":"89","author":"Chiodini","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib98","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1210\/jc.2009-0468","article-title":"Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study","volume":"94","author":"Chiodini","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib99","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1210\/jc.2016-1423","article-title":"Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas","volume":"101","author":"Morelli","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-15-0977","article-title":"Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism","volume":"174","author":"Salcuni","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib101","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/jbmr.1648","article-title":"Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism","volume":"27","author":"Eller-Vainicher","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.steroids.2010.08.007","article-title":"Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing\u2019s syndrome","volume":"76","author":"Sereg","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.beem.2021.101515_bib103","first-page":"105","article-title":"The impact of mild autonomous cortisol secretion on bone turnover markers","author":"Athimulam","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib104","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","article-title":"Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice","volume":"21","author":"Lane","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib106","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2021.101515_bib107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00223-020-00687-2","article-title":"Glucocorticoids enhanced osteoclast autophagy through the PI3K\/Akt\/mTOR signaling pathway","volume":"107","author":"Fu","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2021.101515_bib108","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2021.101515_bib109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib110","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2021.101515_bib111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1210\/jcem-68-1-120","article-title":"Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement","volume":"68","author":"Giustina","year":"1989","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib112","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12020-014-0278-y","article-title":"Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect","volume":"47","author":"Giustina","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib113","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1210\/endo.143.4.8716","article-title":"Characterization of new selective somatostatin receptor subtype-2 (sst 2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment","volume":"143","author":"Tulipano","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2021.101515_bib114","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1210\/endo-127-6-2705","article-title":"Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies","volume":"127","author":"Wehrenberg","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2021.101515_bib115","first-page":"206","article-title":"Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects","volume":"122","author":"Giustina","year":"1990","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib116","first-page":"1301","article-title":"Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy","volume":"74","author":"Giustina","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/07435809309035407","article-title":"Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing\u2019s disease","volume":"19","author":"Giustina","year":"1993","journal-title":"Endocr Res"},{"key":"10.1016\/j.beem.2021.101515_bib118","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000181882","article-title":"Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing\u2019s disease","volume":"35","author":"Giustina","year":"1991","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2021.101515_bib119","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1210\/jcem.85.3.6531","article-title":"Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone","volume":"85","author":"Terzolo","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","article-title":"Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines","volume":"54","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib121","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2017.03.002","article-title":"Growth hormone deficiency in treated acromegaly and active Cushing\u2019s syndrome","volume":"31","author":"Formenti","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib122","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1210\/jc.2011-1600","article-title":"Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the national health and nutrition examination survey (NHANES): 2001-2006","volume":"96","author":"Skversky","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib123","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/EJE-18-0151","article-title":"Management OF endocrine disease: therapeutics of vitamin D","volume":"179","author":"Ebeling","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib124","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/bcp.13652","article-title":"Vitamin D assays and the definition of hypovitaminosis D: results from the first international conference on controversies in vitamin D","volume":"84","author":"Sempos","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2021.101515_bib125","doi-asserted-by":"crossref","first-page":"17454","DOI":"10.1016\/S0021-9258(18)71516-0","article-title":"Effect of hormones and development on the expression of the rat 1,25-dihydroxyvitamin D3 receptor gene. Comparison with calbindin gene expression","volume":"264","author":"Huang","year":"1989","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2021.101515_bib126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib127","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-017-0860-9","article-title":"Diabetes in Cushing disease","volume":"17","author":"Mazziotti","year":"2017","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.beem.2021.101515_bib128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","article-title":"Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects","volume":"152","author":"Bonadonna","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib129","first-page":"664","article-title":"Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases","volume":"158","author":"Sato","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2021.101515_bib130","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.10613","article-title":"Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice","volume":"46","author":"Solomon","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib131","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3899\/jrheum.130041","article-title":"The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study","volume":"40","author":"Majumdar","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2021.101515_bib132","series-title":"Advances in patient safety: from research to implementation","article-title":"Decision support system design and implementation for outpatient prescribing: the safety in prescribing study","volume":"vol. 3","author":"Feldstein","year":"2005"},{"key":"10.1016\/j.beem.2021.101515_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000249","article-title":"Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database","volume":"2","author":"Trijau","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.beem.2021.101515_bib134","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinte.167.6.591","article-title":"Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial","volume":"167","author":"Curtis","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2021.101515_bib135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/art.21446","article-title":"Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"53","author":"Blalock","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib136","first-page":"550","article-title":"Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis","volume":"31","author":"Naunton","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2021.101515_bib137","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.20403","article-title":"Multifaceted intervention to improve rheumatologists\u2019 management of glucocorticoid-induced osteoporosis: a randomized controlled trial","volume":"51","author":"Solomon","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib138","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11154-010-9138-0","article-title":"Compliance and persistence with osteoporosis medications: a critical review of the literature","volume":"11","author":"Silverman","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2021.101515_bib139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","article-title":"Oral bisphosphonate compliance and persistence: a matter of choice?","volume":"22","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib140","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jbmr.4033","article-title":"The effect of biochemical remission on bone metabolism in Cushing\u2019s syndrome: a 2-year follow-up study","volume":"35","author":"Braun","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101515_bib141","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.clnu.2019.11.024","article-title":"Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review","volume":"39","author":"Donini","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.beem.2021.101515_bib142","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2796.2006.01655.x","article-title":"Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update","volume":"259","author":"Boonen","year":"2006","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.beem.2021.101515_bib143","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies","volume":"15","author":"de Nijs","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib144","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002239900705","article-title":"Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol","volume":"65","author":"Schacht","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2021.101515_bib145","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","article-title":"Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial","volume":"125","author":"Buckley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2021.101515_bib146","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s001980050118","article-title":"Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis","volume":"9","author":"Reginster","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib147","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E","article-title":"The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach","volume":"42","author":"Amin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib148","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/er.2018-00126","article-title":"Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions","volume":"40","author":"Bouillon","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2021.101515_bib149","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jc.2018-01414","article-title":"Controversies in vitamin D: summary statement from an international conference","volume":"104","author":"Giustina","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib150","first-page":"CD000952","article-title":"Calcium and vitamin D for corticosteroid-induced osteoporosis","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2021.101515_bib151","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11154-019-09532-w","article-title":"Consensus statement from 2(nd) international conference on controversies in vitamin D","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2021.101515_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10417","article-title":"Controversies in vitamin D: a statement from the third international conference","volume":"4","author":"Giustina","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.beem.2021.101515_bib153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2005.06.020","article-title":"The Vitamin D requirement in health and disease","volume":"97","author":"Heaney","year":"2005","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.beem.2021.101515_bib154","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.beem.2021.101515_bib155","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib156","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group","volume":"339","author":"Saag","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2021.101515_bib157","doi-asserted-by":"crossref","first-page":"h3783","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2021.101515_bib158","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib159","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2021.101515_bib160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2017.8040","article-title":"Association between alendronate use and hip fracture risk in older patients using oral prednisolone","volume":"318","author":"Axelsson","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2021.101515_bib161","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2021.101515_bib162","first-page":"CD001347","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2021.101515_bib163","article-title":"Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.beem.2021.101515_bib164","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","article-title":"Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?","volume":"25","author":"Scillitani","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","article-title":"Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis","volume":"15","author":"Chiodini","year":"2020","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016788","article-title":"Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study","volume":"7","author":"Horton","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.beem.2021.101515_bib167","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2265.2008.03310.x","article-title":"Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures","volume":"70","author":"Chiodini","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib168","first-page":"48","article-title":"Adrenal incidentaloma: effects on bone metabolism","volume":"31","author":"Francucci","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2021.101515_bib169","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF03346473","article-title":"Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing\u2019s syndrome","volume":"32","author":"Tauchmanova","year":"2009","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2021.101515_bib170","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Women\u2019s Health Initiative I. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2021.101515_bib171","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM198011203032102","article-title":"Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen","volume":"303","author":"Weiss","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2021.101515_bib172","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsbmb.2014.03.003","article-title":"An overview of current and emerging SERMs","volume":"143","author":"Komm","year":"2014","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.beem.2021.101515_bib173","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/art.1780371014","article-title":"Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids","volume":"37","author":"Hall","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib174","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","article-title":"Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial","volume":"70","author":"Mok","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beem.2021.101515_bib175","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.1996.00440100065008","article-title":"Testosterone therapy in glucocorticoid-treated men","volume":"156","author":"Reid","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2021.101515_bib176","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/35.6.568","article-title":"A\u00a0randomized trial of testosterone therapy in males with rheumatoid arthritis","volume":"35","author":"Hall","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.beem.2021.101515_bib177","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1210\/jc.2002-021827","article-title":"Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment","volume":"88","author":"Crawford","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib178","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14740338.2018.1430764","article-title":"Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis","volume":"17","author":"Fontalis","year":"2018","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.beem.2021.101515_bib179","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"Dore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beem.2021.101515_bib180","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/13102818.2014.967827","article-title":"Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment","volume":"28","author":"Petranova","year":"2014","journal-title":"Biotechnol Biotechnol Equip"},{"key":"10.1016\/j.beem.2021.101515_bib181","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2015.03.002","article-title":"Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial","volume":"75","author":"Mok","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101515_bib182","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2021.101515_bib183","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2147\/DDDT.S148654","article-title":"Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"13","author":"Yanbeiy","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.beem.2021.101515_bib184","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12020-020-02500-4","article-title":"Are women with osteoporosis treated with denosumab at risk of severe COVID-19?","volume":"70","author":"Formenti","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101515_bib185","first-page":"105","article-title":"Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis","author":"Diker-Cohen","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101515_bib186","doi-asserted-by":"crossref","first-page":"rkaa008","DOI":"10.1093\/rap\/rkaa008","article-title":"The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis","volume":"4","author":"Yamaguchi","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.beem.2021.101515_bib187","first-page":"105","article-title":"Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures","author":"Ding","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2021.101515_bib188","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/rheumatology\/keaa228","article-title":"Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis","volume":"60","author":"Deng","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.beem.2021.101515_bib189","first-page":"2113","article-title":"Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.beem.2021.101515_bib190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib191","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101515_bib192","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101515_bib193","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19877994","article-title":"Update on the safety and efficacy of teriparatide in the treatment of osteoporosis","volume":"11","author":"Minisola","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.beem.2021.101515_bib194","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s40265-019-01145-6","article-title":"Current treatments and new developments in the management of glucocorticoid-induced osteoporosis","volume":"79","author":"Raterman","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2021.101515_bib195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/CE.S172820","article-title":"Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy","volume":"14","author":"Taylor","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.beem.2021.101515_bib196","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2021.101515_bib197","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2021.101515_bib198","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00774-017-0861-4","article-title":"Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis","volume":"36","author":"Ebina","year":"2018","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.beem.2021.101515_bib199","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bonr.2015.03.001","article-title":"Insights on accelerated skeletal repair in Cushing\u2019s disease","volume":"2","author":"Kim","year":"2015","journal-title":"Bone Rep"},{"key":"10.1016\/j.beem.2021.101515_bib200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2021.101515_bib201","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","article-title":"Pituitary tumors centers of excellence","volume":"49","author":"Frara","year":"2020","journal-title":"Endocrinol Metab Clin N Am"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:48Z","timestamp":1761497808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X21000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":201,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1521690X21000324"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2021.101515","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2021.101515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101515"}}